(MYGN) Myriad Genetics - Overview
Stock: Cancer Tests, Health Screens, Genetic Testing, Drug Selection
| Risk 5d forecast | |
|---|---|
| Volatility | 58.6% |
| Relative Tail Risk | -14.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.41 |
| Alpha | -68.95 |
| Character TTM | |
|---|---|
| Beta | 0.977 |
| Beta Downside | 2.124 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.57% |
| CAGR/Max DD | -0.46 |
EPS (Earnings per Share)
Revenue
Risks
Description: MYGN Myriad Genetics March 01, 2026
Myriad Genetics (NASDAQ: MYGN) is a U.S.-based molecular diagnostics firm that delivers DNA- and RNA-based tests across oncology, women’s health, pharmacogenomics, and mental-health segments. Its flagship offerings include the MyRisk hereditary-cancer panel, BRACAnalysis CDx and MyChoice CDx companion diagnostics for BRCA-mutated and ovarian cancers, the Prolaris prostate-cancer prognostic assay, EndoPredict breast-cancer test, as well as prenatal screens such as Prequel and Foresight, and the GeneSight psychotropic-medication guide.
In the most recent quarter (Q3 2024), Myriad reported revenue of $254 million, a 12% year-over-year increase driven primarily by higher utilization of its oncology companion-diagnostic tests. The company’s cash and short-term investments rose to $523 million, providing a solid liquidity cushion, while adjusted EBITDA turned positive at $22 million, reflecting improving cost-structure efficiencies.
Industry-wide, the molecular-diagnostics market is projected to expand at a CAGR of roughly 10% through 2028, fueled by rising cancer incidence, expanding insurance coverage for genomic testing, and accelerating adoption of targeted-therapy companion diagnostics. Myriad’s strategic alliances with Illumina, Memorial Sloan Kettering, and SOPHiA GENETICS position it to capture a growing share of the liquid-biopsy and precision-medicine pipeline.
For a deeper dive into MYGN’s valuation and risk profile, you might explore ValueRay’s analyst tools.
Headlines to watch out for
- Oncology test sales drive revenue growth
- Womens health product adoption impacts market share
- Reimbursement policies for genetic tests influence profitability
- Regulatory approvals for new diagnostics expand market access
- Competition from other diagnostic companies pressures pricing
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -365.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA 1.44 > 1.0 |
| NWC/Revenue: 24.11% < 20% (prev 15.99%; Δ 8.13% < -1%) |
| CFO/TA 0.00 > 3% & CFO 1.80m > Net Income -365.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (93.3m) vs 12m ago 2.41% < -2% |
| Gross Margin: 69.93% > 18% (prev 0.70%; Δ 6.92k% > 0.5%) |
| Asset Turnover: 95.09% > 50% (prev 81.51%; Δ 13.58% > 0%) |
| Interest Coverage Ratio: -36.63 > 6 (EBITDA TTM -399.0m / Interest Expense TTM 10.5m) |
Altman Z'' -9.79
| A: 0.28 (Total Current Assets 332.6m - Total Current Liabilities 133.8m) / Total Assets 706.6m |
| B: -1.59 (Retained Earnings -1.12b / Total Assets 706.6m) |
| C: -0.44 (EBIT TTM -384.6m / Avg Total Assets 867.1m) |
| D: -3.31 (Book Value of Equity -1.12b / Total Liabilities 338.6m) |
| Altman-Z'' Score: -9.79 = D |
Beneish M -3.87
| DSRI: 0.97 (Receivables 115.3m/121.2m, Revenue 824.5m/837.6m) |
| GMI: 1.00 (GM 69.93% / 69.89%) |
| AQI: 0.55 (AQ_t 0.30 / AQ_t-1 0.54) |
| SGI: 0.98 (Revenue 824.5m / 837.6m) |
| TATA: -0.52 (NI -365.9m - CFO 1.80m) / TA 706.6m) |
| Beneish M-Score: -3.87 (Cap -4..+1) = AAA |
What is the price of MYGN shares?
Over the past week, the price has changed by -9.51%, over one month by +3.79%, over three months by -33.33% and over the past year by -51.96%.
Is MYGN a buy, sell or hold?
- StrongBuy: 3
- Buy: 3
- Hold: 6
- Sell: 2
- StrongSell: 1
What are the forecasts/targets for the MYGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.8 | 53.8% |
| Analysts Target Price | 7.8 | 53.8% |
MYGN Fundamental Data Overview March 14, 2026
P/S = 0.5841
P/B = 1.3086
P/EG = 1.2358
Revenue TTM = 824.5m USD
EBIT TTM = -384.6m USD
EBITDA TTM = -399.0m USD
Long Term Debt = 119.9m USD (from longTermDebt, last quarter)
Short Term Debt = 6.90m USD (from shortTermDebt, last quarter)
Debt = 209.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 60.2m USD (from netDebt column, last quarter)
Enterprise Value = 541.8m USD (481.6m + Debt 209.8m - CCE 149.6m)
Interest Coverage Ratio = -36.63 (Ebit TTM -384.6m / Interest Expense TTM 10.5m)
EV/FCF = -33.44x (Enterprise Value 541.8m / FCF TTM -16.2m)
FCF Yield = -2.99% (FCF TTM -16.2m / Enterprise Value 541.8m)
FCF Margin = -1.96% (FCF TTM -16.2m / Revenue TTM 824.5m)
Net Margin = -44.38% (Net Income TTM -365.9m / Revenue TTM 824.5m)
Gross Margin = 69.93% ((Revenue TTM 824.5m - Cost of Revenue TTM 247.9m) / Revenue TTM)
Gross Margin QoQ = 69.97% (prev 69.91%)
Tobins Q-Ratio = 0.77 (Enterprise Value 541.8m / Total Assets 706.6m)
Interest Expense / Debt = 2.10% (Interest Expense 4.40m / Debt 209.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -303.8m (EBIT -384.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.49 (Total Current Assets 332.6m / Total Current Liabilities 133.8m)
Debt / Equity = 0.57 (Debt 209.8m / totalStockholderEquity, last quarter 368.0m)
Debt / EBITDA = -0.15 (negative EBITDA) (Net Debt 60.2m / EBITDA -399.0m)
Debt / FCF = -3.72 (negative FCF - burning cash) (Net Debt 60.2m / FCF TTM -16.2m)
Total Stockholder Equity = 458.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.20% (Net Income -365.9m / Total Assets 706.6m)
RoE = -79.81% (Net Income TTM -365.9m / Total Stockholder Equity 458.4m)
RoCE = -66.50% (EBIT -384.6m / Capital Employed (Equity 458.4m + L.T.Debt 119.9m))
RoIC = -55.45% (negative operating profit) (NOPAT -303.8m / Invested Capital 548.0m)
WACC = 7.13% (E(481.6m)/V(691.4m) * Re(9.52%) + D(209.8m)/V(691.4m) * Rd(2.10%) * (1-Tc(0.21)))
Discount Rate = 9.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.10%
[DCF] Fair Price = unknown (Cash Flow -16.2m)
EPS Correlation: 17.96 | EPS CAGR: 6.37% | SUE: 0.48 | # QB: 0
Revenue Correlation: 86.22 | Revenue CAGR: 6.63% | SUE: 0.36 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.02 | Chg7d=-0.004 | Chg30d=-0.011 | Revisions Net=-2 | Analysts=11
EPS current Year (2026-12-31): EPS=0.06 | Chg7d=-0.001 | Chg30d=-0.009 | Revisions Net=+1 | Growth EPS=-1.7% | Growth Revenue=+5.0%
EPS next Year (2027-12-31): EPS=0.17 | Chg7d=+0.004 | Chg30d=+0.029 | Revisions Net=+2 | Growth EPS=+187.4% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: -0.33 (2 Up / 4 Down within 30d for Next Quarter)